Hypoxia-reoxygenation (H-R) injury is an important clinical phenomenon in patients with coronary artery disease (CAD). Endothelial injury is a critical step in the initiation and progression of atherosclerosis. Therefore, endothelial and cardiomyocyte protection has been considered an effective step in prevention and treatment of CAD. To investigate the cardioprotective effect of tocopherols, omega-3 fatty acid [eicosapentaenoic acid (EPA)] and transforming growth factor-β1 (TGF-β1) during H-R, calcium tolerant myocytes isolated from adult rats were cultured and subjected to hypoxia for 24 hrs followed by reoxygenation of 3 hrs. All strategies, including tocopherol preparations, EPA and TGF-β1, showed attenuation of H-R-induced myocyte injury indicated by reduction of lactate dehydrogenase (LDH) release. Both a-tocopherol and a mixed- tocopherols (α-, γ-, and δ-) decreased the effects of H-R on iNOS expression and SOD activity in cultured myocytes. The mixed-tocopherols was more potent than a-tocopherol alone. EPA inhibited H-R-induced lipid peroxidation, MMP-1 expression and p38MAPK phosphorylation. TGF-β1 blocked the increase in iNOS and PKB phosphorylation as well as the decrease in eNOS expression in cultured myocytes exposed to H-R. To further investigate the protective effect of omega-3 fatty acids [docosahexaenoic acid (DHA) and EPA] and TGF-β1, the cultured endothelial cells were exposed to oxidant injury mediated by oxidized low-density lipoprotein (ox-LDL). Ox-LDL markedly reduced TGF-β1 release, increased the expression of TGF-β1 receptors, upregulated the expression of adhesion molecules, P-selectin and ICAM-1, enhanced the adhesion of monocytes to endothelial cells, and decreased protein kinase B (PKB) activation. Both DHA and EPA blocked these effects of ox-LDL on endothelial cells. Exogenous recombinant TGF-β1 also ameliorated ox-LDL-induced expression of adhesion molecules and monocytes adhesion, which were blocked by antibodies to the TGF-β1 type 2, but not to the type 3 receptor. These observations provide mechanistic insights into H-R and oxidant injury and tissue protection by three different strategies.

La vida aeróbica conlleva la formación de especies reactivas derivadas del oxígeno: el radical hidroxilo (OH·), el ión superóxido (O2·-) y el peróxido de hidrógeno (H2O2). En Schizosaccharomyces pombe, dos rutas controlan las respuestas antioxidantes en respuesta a estrés oxidativo por H2O2: la del factor de transcripción Pap1 y la de la MAP quinasa Sty1. En esta tesis doctoral, hemos determinado que la activación de Pap1 se da en respuesta a dosis moderadas, pero no severas, de H2O2. Hemos identificado a la peroxirredoxina Tpx1 como sensor y transmisor de la señal de estrés oxidativo a Pap1. La inactivación temporal de Tpx1, durante estrés oxidativo severo, por oxidación a sulfínico de su cisteína catalítica inhibe la transmisión de señal a Pap1. En dichas condiciones, se activa la ruta de Sty1, que media la inducción de Srx1, cuya función es reducir y, con ello, reactivar a Tpx1. Finalmente, hemos estudiado el papel esencial de Tpx1 en aerobiosis. / Aerobic life involves formation of reactive oxygen species: hydroxyl radical (OH·), superoxide ion (O2·-) and hydrogen peroxide (H2O2). In Schizosaccharomyces pombe, two pathways respond to H2O2 and trigger independent antioxidant-gene responses: the Pap1 and the Sty1 pathways. In this thesis project, we have determined that the activation of the transcription factor Pap1 occurs only at low, but not elevated, H2O2 concentrations. We have identified the peroxiredoxin Tpx1 as a H2O2-sensor and redox activator of Pap1. The temporal inactivation of Tpx1 during severe oxidative stress, by oxidation of its catalytic cysteine to sulfinic acid, inhibits signal transduction to Pap1. During these conditions, the MAP kinase Sty1 is activated and expression of the sulfiredoxin Srx1 is triggered. Srx1 functions to reduce and thus reactivate Tpx1. Finally, we have analysed the essential function of Tpx1 in aerobiosis.

Les sécrétines peptidiques de l’hormone de croissance (GHRPs) constituent une classe de peptides synthétiques capables de stimuler la sécrétion de l’hormone de croissance (GH). Cette activité est médiée par leur liaison à un récepteur couplé aux protéines G : le récepteur des sécrétines de l’hormone de croissance (GHS-R1a), identifié subséquemment comme le récepteur de la ghréline. La ghréline est un peptide de 28 acides aminés sécrété principalement par les cellules de la muqueuse de l’estomac, qui exerce de nombreux effets périphériques indépendamment de la sécrétion de l’hormone de croissance. Les effets indépendants de la sécrétion de GH incluent, entre autres, des actions sur le contrôle de la prise de nourriture, le métabolisme énergétique, la fonction cardiaque, le système immunitaire et la prolifération cellulaire. L’étude de la distribution périphérique des sites de liaison des GHRPs nous a permis d’identifier un second site, le CD36, un récepteur scavenger exprimé dans plusieurs tissus dont le myocarde, l’endothélium de la microvasculature et les monocytes/macrophages. Le CD36 exprimé à la surface du macrophage joue un rôle clé dans l’initiation du développement de l’athérosclérose par la liaison et l’internalisation des lipoprotéines de faible densité oxydées (LDLox) dans l’espace sous-endothélial de l’artère. L’hexaréline, un analogue GHRP, a été développé comme agent thérapeutique pour stimuler la sécrétion de l’hormone de croissance par l’hypophyse. Sa propriété de liaison aux récepteurs GHS-R1a et CD36 situés en périphérie et particulièrement sa capacité d’interférer avec la liaison des LDLox par le CD36 nous ont incité à évaluer la capacité de l’hexaréline à moduler le métabolisme lipidique du macrophage. L’objectif principal de ce projet a été de déterminer les effets de l’activation des récepteurs CD36 et GHS-R1a, par l’hexaréline et la ghréline, le ligand endogène du GHS-R1a, sur la physiologie du macrophage et de déterminer son potentiel anti-athérosclérotique. Les résultats montrent premièrement que l’hexaréline et la ghréline augmentent l’expression des transporteurs ABCA1 et ABCG1, impliqués dans le transport inverse du cholestérol, via un mécanisme contrôlé par le récepteur nucléaire PPARγ. La régulation de l’activité transcriptionnelle de PPARγ par l’activation des récepteurs CD36 et GHS-R1a se fait indépendamment de la présence du domaine de liaison du ligand (LBD) de PPARγ et est conséquente de changements dans l’état de phosphorylation de PPARγ. Une étude plus approfondie de la signalisation résultant de la liaison de la ghréline sur le GHS-R1a révèle que PPARγ est activé par un mécanisme de concertation entre les voies de signalisation Gαq/PI3-K/Akt et Fyn/Dok-1/ERK au niveau du macrophage. Le rôle de PPARγ dans la régulation du métabolisme lipidique par l’hexaréline a été démontré par l’utilisation de macrophages de souris hétérozygotes pour le gène de Ppar gamma, qui présentent une forte diminution de l’activation des gènes de la cascade métabolique PPARγ-LXRα-transporteurs ABC en réponse à l’hexaréline. L’injection quotidienne d’hexaréline à un modèle de souris prédisposées au développement de l’athérosclérose, les souris déficientes en apoE sous une diète riche en cholestérol et en lipides, se traduit également en une diminution significative de la présence de lésions athérosclérotiques correspondant à une augmentation de l’expression des gènes cibles de PPARγ et LXRα dans les macrophages péritonéaux provenant des animaux traités à l’hexaréline. L’ensemble des résultats obtenus dans cette thèse identifie certains nouveaux mécanismes impliqués dans la régulation de PPARγ et du métabolisme du cholestérol dans le macrophage via les récepteurs CD36 et GHS-R1a. Ils pourraient servir de cibles thérapeutiques dans une perspective de traitement des maladies cardiovasculaires. / Growth hormone-releasing peptides (GHRPs) are a class of small synthetic peptides known to stimulate GH release through their binding to a G protein-coupled receptor identified as GHS-R1a, later recognized as the ghrelin receptor. Ghrelin is an acetylated 28 amino acid hormone initially identified from the stomach, which induces the release of growth hormone (GH) from the pituitary but also regulates food intake, energy homeostasis, cardiovascular function, immune system and cell proliferation. In documenting the peripheral distribution of GHRPs binding sites, we uncovered the presence of another binding site for GHRPs, identified as CD36, a class B scavenger receptor. CD36 is expressed among several tissues, including myocytes, endothelial cells of the microvasculature and monocytes/macrophages. The macrophage CD36 contributes to excessive lipid loading and atherogenic formation of foam cells through uptake of oxidized low-density lipoprotein (oxLDL) in the subendothelial space of the artery. The properties of hexarelin, a ligand for GHS-R1a and CD36, which features overlapping binding sites with that of oxLDL binding domain on CD36, and thus interfering with the binding of oxLDL on CD36, have prompted us to evaluate the potential of hexarelin, as well as that of the endogenous ligand ghrelin in the modulation of macrophage cholesterol metabolism. We demonstrate here the ability of hexarelin and ghrelin to enhance the expression of ATP-binding cassette A1 and G1 transporters through a PPARγ-dependent mechanism. The hormone binding domain of PPARγ is not required to mediate PPARγ transcriptional activation by CD36 and GHS-R1a. Both hexarelin and ghrelin promotes phosphorylation of PPARγ in THP-1 macrophages. A more detailed study of GHS-R1a-initiated signaling revealed an intricate and complex signalling interplay triggered by ghrelin that involves modulation of Src-dependent Dok-1/ERK1/2 and Src-independent Gαq/PI3-K/Akt pathways, leading to PPARγ-dependent transcriptional competence in the macrophages. The central role of PPARγ on cholesterol metabolism in the macrophages has been demonstrated using peritoneal macrophages from PPARγ heterozygote mice whose response to hexarelin on PPARγ-LXRα-ABC transporters pathway was strongly impaired. Treatment of apolipoprotein E-null mice fed on a lipid-rich diet with hexarelin resulted in a significant reduction in atherosclerotic lesions, concomitant with an enhanced expression of PPARγ and LXRα target genes in peritoneal macrophages. The results presented in this thesis feature novel mechanisms by which the beneficial regulation of PPARγ and cholesterol metabolism in macrophages could be regulated by both CD36 and ghrelin receptor. The downstream effects following the activation of these receptors might be potential targets in the treatment of human coronary artery disease.

Recent literature has shown that AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors lacking the GluR2 subunit (thus calcium permeable) are widely expressed in the CNS, especially in interneurons and glia, where they contribute to synaptic transmission and plasticity. Studies have also indicated that calcium permeable AMPARs (CP-AMPARs) are expressed and participate in synaptic regulation in principal neurons, including hippocampal pyramidal neurons. Furthermore, CP-AMPARs and their resultant calcium influx are implicated in various pathophysiological conditions such as ischemia and seizures. However, the synaptic events activated by calcium influx through CP-AMPARs remain unknown. I took advantage of genetically altered mice without (GluR2-/-) or with reduced GluR2 (GluR2+/-), thus allowing the expression and detailed analysis of synaptic CP-AMPARs in hippocampal pyramidal neurons. Utilizing electrophysiological techniques, I demonstrated that these receptors were capable of inducing numerous forms of long-term potentiation (referred to as CP-AMPAR-dependent LTP) through a number of different induction protocols, including high-frequency stimulation (HFS) and theta-burst stimulation (TBS). This included a previously undemonstrated form of protein-synthesis dependent late-LTP (L-LTP) at CA1 synapses that is NMDA-receptor (NMDAR) independent. This form of plasticity was completely blocked by the selective CP-AMPAR inhibitor IEM-1460. Surprisingly, calcium/calmodulin-dependent kinase II (CaMKII), the key protein kinase that is indispensable for NMDAR-dependent LTP at CA1 synapses appeared to be not required for the induction of CP-AMPAR-dependent LTP due to the lack of effect of two separate pharmacological inhibitors (KN-62 and staurosporine) on this form of potentiation. Both KN-62 and staurosporine strongly inhibited NMDAR dependent LTP in control studies. In contrast, inhibitors for the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) cascade (PD98059 and U0126) significantly attenuated this CP-AMPAR-dependent LTP. Additional studies with knockout mice revealed that the ERK/MAPK signalling cascade is likely acting through p-21 activated kinase 1 (or PAK1, a Rho-GTPase associated kinase) dependent mechanisms. These results suggest that distinct synaptic signalling underlies GluR2-lacking CP-AMPAR-dependent LTP, and reinforces the recent notions that CP-AMPARs are important facilitators of synaptic plasticity in the brain.

Recent literature has shown that AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors lacking the GluR2 subunit (thus calcium permeable) are widely expressed in the CNS, especially in interneurons and glia, where they contribute to synaptic transmission and plasticity. Studies have also indicated that calcium permeable AMPARs (CP-AMPARs) are expressed and participate in synaptic regulation in principal neurons, including hippocampal pyramidal neurons. Furthermore, CP-AMPARs and their resultant calcium influx are implicated in various pathophysiological conditions such as ischemia and seizures. However, the synaptic events activated by calcium influx through CP-AMPARs remain unknown. I took advantage of genetically altered mice without (GluR2-/-) or with reduced GluR2 (GluR2+/-), thus allowing the expression and detailed analysis of synaptic CP-AMPARs in hippocampal pyramidal neurons. Utilizing electrophysiological techniques, I demonstrated that these receptors were capable of inducing numerous forms of long-term potentiation (referred to as CP-AMPAR-dependent LTP) through a number of different induction protocols, including high-frequency stimulation (HFS) and theta-burst stimulation (TBS). This included a previously undemonstrated form of protein-synthesis dependent late-LTP (L-LTP) at CA1 synapses that is NMDA-receptor (NMDAR) independent. This form of plasticity was completely blocked by the selective CP-AMPAR inhibitor IEM-1460. Surprisingly, calcium/calmodulin-dependent kinase II (CaMKII), the key protein kinase that is indispensable for NMDAR-dependent LTP at CA1 synapses appeared to be not required for the induction of CP-AMPAR-dependent LTP due to the lack of effect of two separate pharmacological inhibitors (KN-62 and staurosporine) on this form of potentiation. Both KN-62 and staurosporine strongly inhibited NMDAR dependent LTP in control studies. In contrast, inhibitors for the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) cascade (PD98059 and U0126) significantly attenuated this CP-AMPAR-dependent LTP. Additional studies with knockout mice revealed that the ERK/MAPK signalling cascade is likely acting through p-21 activated kinase 1 (or PAK1, a Rho-GTPase associated kinase) dependent mechanisms. These results suggest that distinct synaptic signalling underlies GluR2-lacking CP-AMPAR-dependent LTP, and reinforces the recent notions that CP-AMPARs are important facilitators of synaptic plasticity in the brain.

No description available.

No description available.

No description available.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / The renin-angiotensin-aldosterone system (RAAS) is very important during pregnancy, working mainly through the angiotensin II (Ang II) that can interfere with the activation of Mitogenic-Activated Protein Kinases (MAPK) cascade. In addition, pregnancy is associated with marked increase in renal hemodynamics that may also be affected by diabetes mellitus (DM). The objectives were to evaluate the effects of DM induced in Wistar rats during pregnancy and maintained in the postpartum period on the renal expression of PCNA (Proliferating Cell Nuclear Antigen), α-SMA (Smooth Muscle Actin) and p-p38 and p-JNK MAPK as well as in studies of renal function and systolic blood pressure (SBP) in Wistar rats. For this, there were two groups (G): non-pregnant and pregnant. In the first G, the rats were divided into: G1 (non-pregnant controls rats), females that received intraperitoneal injection (ipi) of 0.9% saline solution and G2 (non-pregnant diabetic rats), females that received ipi of alloxan (100 mg/kg) diluted in 0.9% saline solution. In the second G, pregnant rats were divided into: G3 (control mothers), mothers that received ipi of 0.9% saline solution and G4 (diabetic mothers), mothers that received ipi of alloxan (100 mg/kg) diluted in 0.9% saline solution. Blood glucose was observed 2 days after induction and the animals were considered diabetic if they had blood glucose higher than or equal to 150 mg/dL. About 50 days after delivery for G3 and G4 and corresponding time for G1 and G2, the rats were subjected to indirect measurement of SBP by plethysmography and the determination of glomerular filtration rate (GFR) by creatinine clearance. Then, the animals were anesthetized and their kidneys were removed for histological, immunohistochemical and morphometric studies. The results showed that G2 and G4 animals had blood glucose levels (mg/dL) and urinary volume (mL) higher than animals from G1 and G2, even several days after DM induction. The SBP (mmHg) were not different among the groups, but there was a tendency for reduction in GFR (mL/min) from G4 when compared to the other G. There was also a significant increase in kidney weight (right and left)/body weight ratio of G4 in relation to other G. Morphometric analysis showed a reduction of total renal sectional area from G4 and an increase in G3. The glomerular area and the capsular space did not differ between G studied, but there was an augment in glomerular tuft area in G3 and G4. Quantification of the percentage of cortical collagen showed that G2 and G4 presented higher distribution, while the identification and count of mast cells did not differ between G. Regarding PCNA immunoreactivity, G3 showed increased glomerular proliferating cells, while in G4 it was decreased. On the other hand, in the tubulointerstitial (TBI) compartment cell proliferation was higher in G4. Glomerular expression of α-SMA and TBI were increased in G4 compared to other G. Immunoreaction for glomerular p-p38 expression showed a pattern similar to PCNA, with a reduction of p-p38 in G4 relative to other G. The immunoreactivity of p-JNK was higher in both the glomeruli and TBI compartment in G4 compared to G1, G2 and G3. It is concluded that the DM induced during pregnancy and maintained in the postpartum period in Wistar rats resulted in significant structural changes and moderate functional impairmet in kidney, showing that pregnancy has an enhancing effect of renal damage induced by diabetes and these alterations may be related to changes in the expression of p-p38 and p-JNK MAPK. / O sistema renina-angiotensina-aldosterona (SRAA) é de suma importância durante a gestação, atuando principalmente através da angiotensina II (Ang II) que pode interferir na ativação da cascata de Mitogenic-Activated Protein Kinases (MAPK). Além disso, a gravidez está associada a aumentos marcantes na hemodinâmica renal, que também pode ser afetada pelo diabetes mellitus (DM). Os objetivos do trabalho foram avaliar os efeitos do DM induzido em ratas Wistar durante a gestação e mantido no período pós-parto na expressão renal de PCNA (Proliferating Cell Nuclear Antigen), α-SMA (Smooth Muscle Actin) e das MAPKs p-p38 e p-JNK, bem como nos estudos de função renal e pressão arterial sistólica (PAS) de ratas Wistar. Para isso, foram realizados dois grupos (G): não-gravídico e gravídico. No primeiro G, as ratas foram divididas em: G1 (controles sem gravidez), fêmeas que receberam injeção intraperitoneal (iip) de solução salina 0,9% e G2 (diabéticas sem gravidez), fêmeas que receberam iip de aloxana (100mg/kg) diluída em solução salina 0,9%. No segundo G, as ratas grávidas foram divididas em: G3 (mães controles), mães que receberam iip de solução salina 0,9% e G4 (mães diabéticas), mães que receberam iip de aloxana (100mg/kg) diluída em solução salina 0,9%. A glicemia foi verificada 2 dias após a indução e os animais foram considerados diabéticos se apresentassem glicemia maior ou igual a 150mg/dL. Cerca de 50 dias após o parto para G3 e G4 e em tempo correspondente para G1 e G2, as ratas foram submetidas à aferição indireta de PAS por pletismografia, bem como à determinação da Taxa de Filtração Glomerular (TFG) pelo clearance de creatinina. Em seguida, os animais foram anestesiados e tiveram seus rins retirados para as análises histológica, morfométrica e imunohistoquímica. Os resultados mostraram que os animais de G2 e G4 apresentaram glicemia (mg/dL) e volume urinário (mL) maiores que os animais de G1 e G2 vários dias pós-indução do DM do tipo 1. Os valores de PAS (mmHg) não foram diferentes entre os grupos analisados, mas constatou-se uma tendência à redução da TFG (mL/min) de G4 quando comparado aos demais G. Observou-se também um aumento significativo da relação peso rim/peso do corpo (direito e esquerdo) dos animais de G4 em relação aos demais G. As análises morfométricas evidenciaram redução da área de secção renal total de G4 e aumento em G3. A área glomerular e o espaço capsular não diferiram entre os G estudados, mas houve aumento da área de tufo glomerular em G3 e G4. A quantificação da porcentagem de colágeno cortical mostrou que G2 e G4 tiveram maior expressão, ao passo que a identificação e contagem de mastócitos não diferiram entre os G. Quanto à imunorreação para PCNA, o G3 apresentou aumento de células PCNA+ glomerulares, ao passo que em G4 diminuiu. Por outro lado, no compartimento tubulointersticial (TBI) a proliferação celular foi maior em G4. Já a expressão de α-SMA glomerular e TBI foram aumentadas em G4 em comparação aos demais G. A marcação para p-p38 glomerular apresentou um padrão de expressão semelhante ao PCNA, com redução de células p-p38+ em G4 em relação aos outros G. A imunorreação para p-JNK mostrou-se elevada tanto nos glomérulos quanto no compartimento TBI de G4 em relação a G1, G2 e G3. Conclui-se que o DM induzido durante a gestação e mantido no período pós-parto em ratas Wistar resultou em alterações estruturais significativas e funcionais renais moderadas, evidenciando que a gravidez possui um efeito intensificador dos danos renais induzidos pelo diabetes e que estas alterações podem estar relacionadas com as mudanças na expressão das MAPK p-p38 e p-JNK. / Mestre em Biologia Celular e Estrutural Aplicadas

Introduction AP2α is a 52 kDa retinoic acid inducible and developmentally regulated activator of transcription, which binds to the DNA in a sequence-specific manner. Transcription factor AP-2α was isolated from HeLa cells by affinity chromatography using specific binding sites with in SV40 and human metallothionein promoters. Further screening of HeLa cDNA library with oligonucleotide probes predicted partial peptide sequence which led to the isolation of AP-2α cDNA and subsequently it was mapped to chromosome 6 near HLA locus. A differentially spliced version of AP-2α, which lacks most of the C-terminus, encodes a dominant negative protein (AP-2B). Subsequent studies led to the identification of four more isoforms: AP-2β, AP-2γ, AP-2δ and AP-2ε. AP-2 family members can form homo or hetero dimers among themselves through the unique C-terminal helix span helix motif and bind DNA through basic domain lies N-terminus of DNA binding domain. Several evidences suggest that AP-2α can act as a tumor suppressor gene. It has been shown that AP-2α can activate growth suppressor genes like p21WAF1/CIP1. Transforming viral oncogenes like adenovirus E1A and SV40 large T antigen have been shown to alter AP-2α function. In addition, reduced expression of AP-2α has been reported in human breast, ovary, colon, skin, brain and prostate cancers. Further, supporting evidences suggest that more invasiveness and tumorogenicity was observed when dominant negative mutant of AP-2α was expressed in melanoma cells. In this work, we have carried out a systematic study to find the various signal transduction pathways which regulate AP-2 activity as well as we attempted to demonstrate the importance of DNA binding domain in the growth inhibitory functions of AP-2α. HDAC inhibitors (HDIs) activate AP-2 activity through spleen tyrosine kinase (Syk) In the literature, ample evidences are available that genotoxic drugs such as adriamycin, induce tumor suppressors like p53 and p73. In this study, we have screened pharmacological drugs which damage DNA and specific inhibitors of various signal transduction pathways for their ability to activate AP-2 activity. AP-2 specific reporter, 3Χ-AP2-CAT was used in this study to measure the AP-2 activity. Of all the compounds studied, we found that Histone Deacetylase Inhibitors (HDIs) efficiently activated AP-2 activity and was found to be specific as they failed to activate 3X-AP2 mut CAT, which contains mutated AP-2 binding sites as well as pGL tk Luc, which contains thymidine kinase minimal promoter and no AP-2 binding sites. To understand the mechanism of HDI-mediated of AP-2 activation, AP-2 isoforms and its coactivators transcript and protein levels were analyzed. We found significant change in transcript levels of the some of the molecules tested. While the endogenous protein levels of various AP-2 isoforms were undetectable, we found stabilization of AP-2α protein expressed from exogenous source in cells treated with HDIs. HDI stabilized AP-2α was found to be functionally active as it showed increased sequence-specific DNA-binding as well as increased apoptosis. While HDIs known for their ability to modulate the gene activities by chromatin remodeling, it is also known that they alter various signal transduction pathways. In an effort to find pathway(s) by which HDIs activate AP-2 activity, we found that HDIs failed to activate AP-2 reporter in the presence of staurosporine suggesting the involvement a staurosporine sensitive pathway(s) in this process. Stauosporine is a non-specific kinase inhibitor of different signaling pathways. Further studies using different pathway specific inhibitors identified that spleen tyrosine kinase (Syk) is essential for HDIs mediated activation of AP-2 activity. Syk is a non receptor tyrosine kinase which is known to be activated in stress conditions. Syk is considered to be a tumor suppressor since Syk over expression leads to growth suppression of breast cancer cells and is also inactivated in a subset of breast cancers. These results suggest that HDI mediated activation of AP-2 involves AP-2α stabilization through Syk pathway. Regulation of AP-2 by MAP kinase pathway Cell growth, differentiation, and apoptosis are mediated by the activation of mitogenactivated protein kinase (MAPK) pathways. These kinases constitute MAP kinase cascades mainly regulated through phosphorylation status. In mammalian cells, at least four MAPKs, namely, extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinase/stress-activated protein kinases (JNK/SAPKs), p38 and ERK5/big MAP kinase have been identified. The ERKs are usually activated by mitogenic stimuli which in turn increase the proliferation and survival. Over expression of any activator of this signaling cascade lead to the unregulated proliferation of cells. In many cancers, ERK pathways are known to be up regulated. In this study, we found that MEK (MEK is the immediate upstream regulator of ERK) inhibitors - PD98059 and U0126 activate 3X-AP2-CAT suggesting that AP-2 activity is repressed by activated MAP kinase pathway. MEK inhibitor mediated activation was found to be specific because they failed to activate transcription from pGL tk Luc which contains thymidine kinase minimal promoter and no AP-2 binding sites. To understand the mechanism of MEK inhibitor-mediated of AP-2 activation, AP-2 isoforms and its coactivators transcript and protein levels were analyzed. We found significant change in transcript levels of the some of the molecules tested. The endogenous protein levels of various AP-2 isoforms were undetectable. When AP-2α was exogenously expressed, while no change in protein levels and DNA-binding ability was seen, we found evidence for appearance of post-ranslationally modified AP-2α protein in U0126 treated cells. We also found CITED2 (CBP/p300-interacting transactivator 2, co-activator of AP-2α) transcript levels were up regulated in UO126 treated cells. Post translational modifications of AP-2α and increased and increased CITED2 levels may be responsible for MEK inhibitor mediated AP-2 activation. Thus we conclude that ERK pathway, which is an oncogenic MAP kinase pathway, inhibits AP-2 activity thereby suggesting the importance of down regulation of AP-2 activity during transformation. Essential role of DNA-binding domain of AP-2α for its growth inhibitory functions Transcription factor AP-2α has three distinct domains, N-terminal transactivation domain (52-108 aa), C-terminal DNA binding domain (204-408 aa) and dimerization domain (277-395 aa) which lies within the DNA binding domain. AP-2α exerts its effects through binding to specific DNA sequence in the promoter of its target genes leading to either repression or activation. Recent evidences suggest that AP-2α represses many genes through its competitive binding to overlapping AP-2 and other transcription factor binding sites. This suggests an important role exclusively for the DNA binding domain in AP-2α mediated functions. To address the importance of DNA binding domain for AP-2α mediated apoptosis, we have tested the ability different deletion/point mutants of AP-2α with varying DNA binding and transactivation capability to perform growth suppressor function and ability to induce apoptosis. Replication-deficient recombinant adenoviruses expressing different mutants were used in this study. We found that an intact DNA-binding domain alone even in the absence of activation domain is sufficient for AP-2α to inhibit colony formation and to induce significant levels of apoptosis. These results suggest an important role for DNA binding domain growth inhibitory functions of AP-2α and thereby implying the importance of transcriptional repression in AP-2α functions.